Navigation Links
Novel tuberculosis vaccine in Germany in clinical phase
Date:9/11/2008

For the first time in more than 80 years a promising live vaccine against tuberculosis has passed into the clinical phase in Germany: Since Monday of this week the new vaccine, which goes by the designation "VPM1002", has begun safety testing on volunteers in a Phase I clinical trial in Neuss, Germany. It is based on a highly safe vaccine that was introduced in 1921. However, the vaccine has been genetically developed to an extent where it is significantly more effective at preventing infection with tuberculosis bacteria than its predecessor. So far, VPM1002 has proved to be extremely effective and safe in animal models. This good protection now has to be proven in humans for the vaccine to be ready for the final approval," explains the Chief Executive Officer of Vakzine Projekt Management GmbH (VPM), Bernd Eisele.

VPM coordinates application-oriented development of vaccines. The organisation is a public-private partnership established by the Federal Ministry of Education and Research (BMBF) and Helmholtz Centre for Infection Research in 2002. We ensure that the outstanding results of basic science are actually used for the good of mankind and make their way into use," says the Clinical Project Manager Hans von Zepelin. In this, the superb contacts enjoyed by VPM within German science prove a great aid, as the Scientific and Technical Services Manager at the Helmholtz Centre for Infection Research, Rudi Balling, states: "VPM knows exactly where promising projects can be found. With their assistance we, the researchers, can show that our ideas are helping people to stay healthy."

With the financial support of the BMBF VPM was able to licence the novel tuberculosis vaccine from the Max Planck Institute for Infection Biology. The scientific foundation was established in this institute by its Founding Director Stefan H.E. Kaufmann. "The new vaccine is based on the most administered live-vaccine worldwide: Bacille Calmette-Gurin (BCG). However, BCG often fails to display effects anymore. We wanted to sharpen the blunted weapon that is BCG once again."

How this was achieved is described by Leander Grode, at that time a research assistant with Stefan H.E. Kaufmann and now Project Manager at VPM: "The weakened vaccine was genetically modified in such a way to ensure that it is no longer able to hide from the human immune system and even stimulates the body's own defences now." For that a gene of a different bacterium, Listeria, was inserted into the vaccine. "Macrophages of the human immune system take up the vaccine immediately. There it ends up in phagosomes", says Grode. "Due to the genetic modification the bacteria can leave the phagosomes and are then present in the middle of the immune cell this alarms the rest of the immune system, which is then armed to repel real tuberculosis pathogens."


'/>"/>

Contact: Hanner Schlender
hannes.schlender@helmholtz-hzi.de
49-531-618-11400
Helmholtz Association of German Research Centres
Source:Eurekalert  

Related medicine news :

1. VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients
2. Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
3. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
4. NIH scientists find a novel mechanism that controls the development of autoimmunity
5. Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
6. Novel Diagnostic Marker for Acute Kidney Injury Previewed at Abbott-Sponsored Scientific Workshop
7. Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
8. Finding suggests novel ways to boost vaccination or natural defenses
9. Novel hydrogel systems for dentin regeneration
10. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
11. Novel model of osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel tuberculosis vaccine in Germany in clinical phase
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Act (BCRA), their proposed healthcare bill to repeal and replace the Affordable Care ... Senate bill would make significant cuts to Medicaid, a public health insurance program ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own ... others prefer to read it, and some people don't like it at all. FindaTopDoc ... what they found: , Erotic literature can give readers a taste of their deepest, ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia Leaders ... leaders from government, business and civil society in 11 countries across the Middle East ... engaging in a transformative exchange of knowledge and ideas with the leading minds in ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Ulster University, ... June, 2017 from 9 am to 3 pm to present to graduate students exciting ... is an original curriculum project led by The Health Improvement Service of the ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an eastern ... access to asset protection and financial planning services, is teaming up with the ... lives of children with cancer and other chronic diseases. , The For A ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... WAYNE, N.J. , June 16, 2017 Datascope Corp. ... sold by Datascope Corp. for a potential electrical test failure code.     ... PRODUCT PART NUMBER ... CS100 IABP CS300 IABP ... ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/9/2017)... , June 9, 2017 More than 400 ... effort to help spread lessons learned from clinical research ... Diabetes Federation (IDF) and Eli Lilly and Company (NYSE: ... second phase of the Bringing Research in Diabetes to ... commitment to helping people with diabetes effectively manage their ...
Breaking Medicine Technology: